Abstract: A volumetric detection system (or leak tester) is disclosed herein. While the system can have any suitable feature, in some cases, it includes a displacement mechanism (such as a programmable stepper motor), a controllable element (such as a piston) that is coupled to the displacement mechanism, a containment chamber that receives a portion of the controllable element, a sensing unit (or sensor) that is configured to measure a backpressure from a device that is being tested, a computational unit (or processor) that is configured to determine a placement of the controllable element within the chamber, and a coupler (or attachment mechanism) that is configured to couple to the device that is to be tested. In some cases, the system functions without being coupled to a compressed air source. Other implementations are described.

Abstract: An aerosolization apparatus comprises a housing defining a chamber having one or more air inlets. The chamber is sized to receive a capsule which contains an aerosolizable pharmaceutical formulation. The aerosolization apparatus further comprises a puncturing mechanism within the housing. The puncturing mechanism comprises an alignment guide and a puncture member, wherein the alignment guide comprises a surface adapted to contact the capsule while the puncture member is advanced into the capsule to create an opening in the capsule. At least a portion of the surface is sloped relative to the longitudinal axis of the capsule. Alternatively or additionally, the surface may comprise one or more protrusions. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the capsule through the opening created in the capsule.

Abstract: The invention relates to UBE3A protein targets and their usage as target engagement biomarkers for compounds that modulate ube3a expression.

Abstract: The present invention relates to the use of HTRA1 mRNA antagonists in the treatment of eye disorders, such as macular degeneration, and the use of an HTRA1 levels in the aqueous and vitreous humor as a diagnostic biomarker for the suitability of treatment of a subject with an HTRA1 mRNA antagonist.

Abstract: An aerosolization apparatus comprises a housing defining a chamber having one or more air inlets. The chamber is sized to receive a capsule which contains an aerosolizable pharmaceutical formulation. The aerosolization apparatus further comprises a puncturing mechanism within the housing. The puncturing mechanism comprises an alignment guide and a puncture member, wherein the alignment guide comprises a surface adapted to contact the capsule while the puncture member is advanced into the capsule to create an opening in the capsule. At least a portion of the surface is sloped relative to the longitudinal axis of the capsule. Alternatively or additionally, the surface may comprise one or more protrusions. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the capsule through the opening created in the capsule.

Abstract: An aerosolization apparatus comprises a housing defining a chamber having one or more air inlets. The chamber is sized to receive a capsule which contains an aerosolizable pharmaceutical formulation. The aerosolization apparatus further comprises a puncturing mechanism within the housing. The puncturing mechanism comprises an alignment guide and a puncture member, wherein the alignment guide comprises a surface adapted to contact the capsule while the puncture member is advanced into the capsule to create an opening in the capsule. At least a portion of the surface is sloped relative to the longitudinal axis of the capsule. Alternatively or additionally, the surface may comprise one or more protrusions. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the capsule through the opening created in the capsule.

Abstract: An aerosolization apparatus comprises a housing defining a chamber having a plurality of air inlets. The chamber contains an aerosolizable pharmaceutical formulation or is sized to receive a receptacle which contains an aerosolizable pharmaceutical formulation. A shield covers at least one of the air inlets or a portion of at least one of the air inlets. The shield prevents blockage of the air inlet by a user grasping the apparatus and inadvertently covering the air inlet. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the receptacle.

Abstract: A photovoltaic semiconductor solution comprising at least an equimolar mixture of cadmium, tellurium, gallium and indium; propylene glycol flux; carbon; resin in an organic solvent; strontium titanate; and high molecular weight polymer. The photovoltaic semiconductor solution provides charged free electrons on application of light to the photovoltaic semiconductor solution. Another embodiment relates to a solar cell comprising first and second electrode layers; a photovoltaic semiconductor layer disposed between the first and second electrodes; a first membrane disposed between the first electrode and the semiconductor layer and a second membrane disposed between the second electrode and the semiconductor layer. The first membrane is an electron acceptor layer and the second membrane in an insulator. The PV semiconductor layer includes the PV semiconductor solution. Each of the layers of the solar cell are formed on a substrate.

Abstract: An aerosolization apparatus comprises a housing defining a chamber having a plurality of air inlets. The chamber contains an aersolizable pharmaceutical formulation or is sized to receive a receptacle which contains an aerosolizable pharmaceutical formulation. A shield covers at least one of the air inlets or a portion of at least one of the air inlets. The shield prevents blockage of the air inlet by a user grasping the apparatus and inadvertently covering the air inlet. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the receptacle.

Abstract: An aerosolization apparatus comprises a housing defining a chamber having a plurality of air inlets. The chamber contains an aersolizable pharmaceutical formulation or is sized to receive a receptacle which contains an aerosolizable pharmaceutical formulation. A shield covers at least one of the air inlets or a portion of at least one of the air inlets. The shield prevents blockage of the air inlet by a user grasping the apparatus and inadvertently covering the air inlet. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the receptacle.

Abstract: An inhaler for producing an inhalable aerosol of a powdered medicament includes an aerosolizing device in the form of a vortex chamber 1. The vortex chamber 1 has a tangential inlet port 3 and an axial port 2. The ratio of the diameter of the vortex chamber 1 to the diameter of the exit port 2 is between 4 and 12. The length of the exit port 2 is less than its diameter. The cross-section of the inlet port 3 is rectangular and is defined at the bottom and at the radially outermost edge by the walls of the vortex chamber 1. The cross-sectional area of the inlet conduit 7, which supplies the medicament in a gas flow to the inlet port 3, decreases in the direction towards the vortex chamber 1. The inlet conduit 7 may be curved. The inhaler is capable of repeatably producing an aerosol of a medicament with a high proportion of particles in the range 1 to 3 microns, while using a 20 relatively small amount of energy.

Abstract: The present invention concerns new methods of fabricating a silicon material comprising phosphorus. The methods allow high levels of phosphorus to be combined with the silicon. In one aspect of the invention a sample of phosphorus is surrounded with a sample of silicon. At least some of the phosphorus is then vaporised and caused to interact with the silicon.

Abstract: The present invention relates to a chromatography column that removes the longitudinal load from the column tube altogether and transfers it to a yoke and stanchion arrangement situated around but external to the column tube. By using the yoke/stanchion system, the central adjuster can be used to move the top end into and out of the housing. Thus, when internal pressure is applied to the column, the tube experiences no longitudinal load. Additionally, the yoke and stanchion design allows for complete removal of the end from the tube without cumbersome disassembly. Moreover, the yoke provides a place to retain the end while the tube is being filled, emptied, cleaned or repaired.

Abstract: The present invention relates to a chromatography column that removes the longitudinal load from the column tube altogether and transfers it to a yoke and stanchion arrangement situated around but external to the column tube. By using the yoke/stanchion system, the central adjuster can be used to move the top end into and out of the housing. Thus, when internal pressure is applied to the column, the tube experiences no longitudinal load. Additionally, the yoke and stanchion design allows for complete removal of the end from the tube without cumbersome disassembly. Moreover, the yoke provides a place to retain the end while the tube is being filled, emptied, cleaned or repaired.

Abstract: A seal on a movable top or bottom plate for use in a chromatography column. The plate is formed of a flow distributor connected to one or more movement rods that control the movement of the top plate within a chromatography column. The plate is formed of two pieces, a flow distributor and a seal plate. The seal plate is mounted on top of the flow distributor and has a seal that is essentially co-terminal with the outer edge of the flow distributor. The seal plate is attached to the flow distributor by one or more pins or threaded bolts and forms a space between them. The one or more pins contain one or more compression means for biasing the seal plate against the flow distributor. An opening is formed in the seal plate for the selective introduction of a pressurized energy source such as compressed air, gas or hydraulic fluid into the space to overcome the compression means. One or more seals are arranged between the seal plate and distributor to maintain the pressurized energy source between the two of them.

Abstract: A method and apparatus for producing a sterile medical solution is disclosed. The method includes providing at least two components, a first component including bicarbonate ions and a second component including glucose or calcium ions, preheating the first component to a first temperature and the second component to a second temperature, heat sterilizing the first and second components separately to a third and fourth temperatures respectively, the third and fourth temperatures being sterilizing temperatures for the first and second components, maintaining the first and second components approximately at their respective third and fourth temperatures, so as to sterilize the first and second components, cooling the first and second components and delivering the first and second components to a mixing device.

Abstract: Methods and apparatus for sterilizing heat sensitive fluids are provided. The methods include providing a first heat sensitive fluid component, providing a second fluid component, heating the second fluid component to a temperature greater than a predetermined sterilizing temperature, mixing the first heat sensitive fluid component with the heated second fluid component to heat the first heat sensitive fluid components and provide a mixed fluid at a temperature at least up to the predetermined sterilizing temperature, and maintaining the mixed fluid at that temperature for a predetermined sterilizing period. Apparatus for carrying out this method is also provided.

Abstract: A method and apparatus for peritoneal dialysis are described The method includes draining a spent fluid from a patient into a second bag in a pressure chamber including a first bag for containing a fresh fluid for supply to a patient and a second bag for containing a spent fluid drained from a patient, by applying a reduced pressure to the second bag while weighing the first and second bags so as to control the draining of the spent fluid and supplying the fresh fluid to the first bag at a predetermined replenishment flow rate during draining of the spent fluid from the patient into the second bag independently of the influence of the reduced pressure. Apparatus for conducting such a method is also included.

Abstract: An inhaler for producing an inhalable aerosol of a powdered medicament includes an aerosolising device in the form of a vortex chamber 1. The vortex chamer 1 has a tangential inlet port 3 and an axial port 2. The ratio of the diameter of the vortex chamber 1 to the diameter of the exit port 2 is between 4 and 12. The length of the exit port 2 is less than its diameter. The cross-section of the inlet port 3 is rectangular and is defined at the bottom and at the radially outermost edge by the walls of the vortex chamber 1. The cross-sectional area of the inlet conduit 7, which supplies the medicament in a gas flow to the inlet port 3, decreases in the direction towards the vortex chamber 1. The inlet conduit 7 may be curved. The inhaler is capable of repeatably producing an aerosol of a medicament with a high proportion of particles in the range 1 to 3 microns, while using a 20 relatively small amount of energy.

Abstract: An aerosolization apparatus comprises a housing defining a chamber having a plurality of air inlets. The chamber contains an aerosolizable pharmaceutical formulation or is sized to receive a receptacle which contains an aerosolizable pharmaceutical formulation. A shield covers at least one of the air inlets or a portion of at least one of the air inlets. The shield prevents blockage of the air inlet by a user grasping the apparatus and inadvertently covering the air inlet. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the receptacle.